Publication date: Sep 20, 2023
Transnasal flexible laryngoscopy is considered an aerosol generating procedure. A negative pressure face shield (NPFS) was developed to control aerosol from the patient during laryngoscopy. The purpose of this study was to determine the effectiveness of the NPFS at controlling virus aerosol compared to a standard disposable plastic face shield. The face shields were placed on a simulated patient coughing machine. MS2 bacteriophage was used as a surrogate for SARS-CoV-2 and was aerosolized using the coughing machine. The aerosolized virus was sampled on the inside and outside of the face shields. The virus aerosol concentration was not significantly different between the inside and outside of the traditional plastic face shield (p = 0. 12). However, the particle concentrations across all particle sizes measured were significantly decreased outside the face shield. The virus and particle concentrations were significantly decreased (p
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | VO | effectiveness |
| drug | DRUGBANK | Coenzyme M |
| disease | VO | Viruses |
| disease | VO | frequency |
| disease | VO | LACK |
| disease | MESH | COVID 19 pandemic |
| disease | VO | nose |
| disease | VO | effective |
| disease | VO | device |
| drug | DRUGBANK | Medical air |
| disease | VO | USA |
| disease | VO | ineffective |
| disease | VO | mouth |
| disease | VO | viable |
| disease | VO | population |
| drug | DRUGBANK | Phosphate ion |
| drug | DRUGBANK | Ethanol |
| disease | IDO | assay |
| disease | VO | viability |
| disease | VO | volume |
| drug | DRUGBANK | Ranitidine |
| disease | MESH | infection |
| disease | VO | Severe acute respiratory syndrome coronavirus 2 |
| drug | DRUGBANK | Riboprine |
| disease | MESH | respiratory infections |
| drug | DRUGBANK | Serine |
| disease | MESH | Influenza |
| disease | MESH | Respiratory Diseases |
| drug | DRUGBANK | Phenylbutyric acid |
| pathway | REACTOME | Reproduction |